| Trial ID: | L0548 |
| Source ID: | NCT01624064
|
| Associated Drug: |
Enalapril
|
| Title: |
Renal Effects of an Angiotensin Converting Enzyme Inhibitor in Adults With Chronic Kidney Disease of Uncertain Aetiology
|
| Acronym: |
CKDu
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Renal Insufficiency, Chronic
|
| Interventions: |
DRUG: Enalapril|DRUG: Calcium Supplement
|
| Outcome Measures: |
Primary: Proteinuria, Numerous clinical trials have established that angiotensin-converting enzyme inhibitors (ACEI) are beneficial in slowing progression of renal disease. However the long-term renal effect of these agents in early renal disease is not well demonstrated. In fact the trials which showed benefits with ACEI did show in glomerular disease and evidence is not so strong in tubulo-interstitial disease., One year|Estimated GFR, In most forms of proteinuric chronic renal disease, glomerular filtration rate continues to decline even when the initial insult has been removed. The cause of CKDu is still unknown. CKDu is a tubulo-interstitial disease with low grade proteinuria. We believe that the place of ACEI for secondary prevention of CKDu progression needs investigation., One year | Secondary: All cause mortality, One year|Cardiovascular mortality, One year
|
| Sponsor/Collaborators: |
Sponsor: Ministry of Health, Sri Lanka | Collaborators: World Health Organization
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1|PHASE2
|
| Enrollment: |
200
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2012-08
|
| Completion Date: |
2013-10
|
| Results First Posted: |
|
| Last Update Posted: |
2012-06-20
|
| Locations: |
General (Teaching) Hospital, Anuradhapura, Anuradhapura, North Central, Sri Lanka
|
| URL: |
https://clinicaltrials.gov/show/NCT01624064
|
